CoChat

Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care

Open access

The DOI matches its Crossref record; 83 of the 87 references it cites were found in a registry or an index; 53 of the 80 sources its claims cite were checked for support.

Abstract

The available data suggest differences in the course of type 2 diabetes mellitus (T2DM) between men and women, influenced by the distinguishing features of the sex. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are a relatively new class of antidiabetic drugs that act by mimicking the function of endogenous glucagon-like peptide 1. They constitute valuable agents for the management of T2DM as, in addition to exerting a strong hypoglycemic action, they present cardiorenal protective properties, promote weight loss, and have a good safety profile, particularly with respect to the risk of hypoglycemia. Due to the precedent of studies having identified sexual dimorphic elements regarding the action of other antidiabetic agents, ongoing research has attempted to examine whether this is also the case for GLP-1 RAs. Until now, sex differences have been observed in the impact of GLP1-RAs on glycemic control, weight reduction, and frequency of adverse events. On the contrary, the question of whether these drugs differentially affect the two sexes with respect to cardiovascular risk and incidence of major adverse cardiovascular events remains under investigation. Knowledge of the potential sex-specific effects of these medications is extremely useful for the implementation of individualized therapeutic plans in the treatment of T2DM. This narrative review aims to present the available data regarding the sex-specific action of GLP-1 RAs as well as to discuss the potential pathophysiologic mechanisms explaining these dissimilarities.

Overview

CoChat Summary

TL;DR

This narrative review examines whether biological sex modifies the efficacy and safety of GLP-1 receptor agonists in type 2 diabetes and obesity. It concludes that women tend to achieve greater weight loss and report more gastrointestinal adverse events, while sex differences in glycemic control and cardiovascular outcomes remain inconsistent and under-investigated.

Key findings

  • Weight loss appears more pronounced in women across several studies: e.g., −7.0 kg vs. −3.3 kg in a retrospective study (p < 0.06); 33% of women vs. 17% of men achieved weight-loss targets after 12 months of exenatide; BMI reduction 4.8 vs. 2.6 kg/m² (p < 0.05); dulaglutide −1.32 kg in females (p = 0.001) vs. +0.09 kg in males (p < 0.001). Liraglutide exposure was 32% higher in women than men of comparable weight.
  • Glycemic efficacy findings are mixed. Some analyses show no sex effect (dulaglutide HbA1c reduction −1.26% in men vs. −1.33% in women; post hoc analysis of 855 patients), while others favor women (exenatide plus metformin reduced HbA1c from 8.8% to 6.8% in women vs. 8.9% to 7.5% in men, p < 0.05; metformin plus liraglutide −1.5 vs. −0.75, p = 0.028) or men (38% vs. 27% achieved HbA1c ≤7% with exenatide twice daily, p = 0.03; male sex predicted treatment failure, OR 2.55).
  • Women report more adverse events, especially gastrointestinal: dulaglutide 86.5% of women vs. 61.4% of men; liraglutide 83.3% vs. 65.5%. A Korean database analysis found women about twice as likely to report any adverse event (reporting ratio 2.34) and higher headache risk (risk ratio 7.97). No significant sex difference was found for nocturnal or total hypoglycemia.
  • Cardiovascular and MACE findings are inconclusive: some studies show no sex divergence (hazard ratio 0.88 in both sexes; meta-analysis p = 0.375), while one study found lower MACE incidence in women (6.6 vs. 11.9 per 1000 person-years, p < 0.001) and a greater risk reduction with GLP-1 RAs vs. sulfonylureas in women (adjusted HR 0.57 vs. 0.82, p = 0.001). Effects on waist circumference, blood pressure, and lipids remain uncertain.

Methods

  • Design: narrative review of available data on sex-specific actions of GLP-1 RAs in type 2 diabetes and obesity.
  • Data: synthesized evidence from clinical trials, pooled and post hoc analyses, retrospective and cohort studies, meta-analyses, pharmacokinetic/exposure analyses, and animal studies.
  • Analysis: narrative synthesis, with tables summarizing drug characteristics, exposure/dose–effectiveness–adverse event relationships, and sex differences. No systematic search strategy or meta-analysis is described.

Limitations

  • Stated by the authors: most referenced studies have heterogeneous patient populations differing in diabetes duration, pharmacologic regimen, and prior medication history; most studies examining sex effects are post hoc analyses with secondary outcomes; and many studies lack sex-disaggregated data.
  • Evident from the text: as a narrative review, it does not describe a systematic search, quality appraisal, or quantitative synthesis; findings across studies are conflicting, and only a small number of studies stratified cardiovascular outcomes by sex.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/jpm12030454

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Sex-specific effects of GLP-1 RAs.
Figure 1 Sex-specific effects of GLP-1 RAs.CC BY · PubMed Central

Verification

Claims the paper makes

49 Valid · 6 Not valid · 21 Not checked · 27 Own results and interpretations

55 more claims · 27 with their cited sources checked

Create a free account to see all 103 claims and to verify the 3 references still open.

See all claims — free account
  • It may state two separate claims as one. 35
  • Probably not a substantial claim. 11
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 83 references

Research works printed but not linked: 5

  1. (2022, February 28). PubChem Exenatide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/45588096.
  2. (2022, February 28). PubChem Liraglutide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/16134956.
  3. (2022, February 28). PubChem Albiglutide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/145994868.
  4. (2022, February 28). PubChem Lixisenatide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/90472060.
  5. (2022, February 28). PubChem Semaglutide, Available online: https://pubchem.ncbi.nlm.nih.gov/compound/56843331.

Cited by

See all 144

Metadata

Authors
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K.
Affiliations
Aristotle University of Thessaloniki (GR)
Corresponding author
Kotsa, Kalliopi
Venue
Journal of Personalized Medicine
Publisher
MDPI AG
Published
2022-03-13
Volume
12
Issue
3
Pages
454
ISSN
2075-4426 (ISSN-L)
OpenAlex
W4221056231
Cited by
140
References
87
Citations by year
2026: 35 · 2025: 44 · 2024: 40 · 2023: 17 · 2022: 4
FWCI
3.74
Type
journal article
Language
en
Open access
Locations
  • Journal of Personalized Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Sex and Gender in Healthcare
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
sex differences, GLP-1 receptor agonists, type 2 diabetes, obesity, glycemic control, weight loss, major adverse cardiovascular events, cardiorenal protection, adverse drug reactions, personalized medicine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care. https://app.cochat.ai/papers/10.3390/jpm12030454
The paper
Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022). Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care. Journal of Personalized Medicine. https://doi.org/10.3390/jpm12030454

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.